INTRODUCTION {#s1}
============

Osteosarcoma is the most common non-haematological primary malignant tumor of the bone, it arises from mesenchymal cells that produce osteoid and immature bone and affects mainly the extremities of adolescents and young adults \[[@R1]--[@R2]\].

The 5-years survival rate for patients with osteosarcoma without evidence of metastasis is 60% to 65%, whereas it is only 20% to 28% for osteosarcoma patients with metastases at the time of diagnosis \[[@R3]\]. Treatment of high grade osteosarcoma is based on a multidisciplinary approach that includes neoadjuvant chemotherapy, surgical excision of the primary tumor and metastasis excision; evaluation of response to therapy in the surgical specimen is crucial to eventually schedule a postoperative chemotherapy \[[@R4]\]. Standard therapy regimens often involve the use of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide \[[@R4]--[@R5]\]. Evaluation of response to therapy was assessed by percentage area of necrosis in the specimen after surgery; patients who respond to therapy showing tumor necrosis ≥ 90% after surgery and they do not develop metastasis (Responder) while patients that do not respond to neoadjuvant chemotherapy showing tumor necrosis ≤ 90% after surgery and eventually developing metastasis (Non-responder) \[[@R6]\].

Although the survival rate has improved considerably after the introduction of neoadjuvant chemotherapy and surgery, metastatic or recurrent disease still occurs and the survival rate of patients is mainly linked to the resistance to therapy and to the development of metastasis \[[@R7]\]. In patients with metastatic osteosarcoma treated with neoadjuvant therapy, the "Responder" status shows improved survival (82% at 5-years) compared to "Non-Responder" (70% at 5-years) \[[@R8]--[@R9]\]. Over the last decade, scientific research has provided essential information about the pathogenic, molecular and biochemical pathway involved in osteosarcoma \[[@R10]--[@R11]\]; however, molecular mechanisms related to carcinogenesis, progression and resistance to therapy are still largely unknown. Indeed, even now the osteosarcoma karyotype is considered complex and only mutations of tumor suppressors genes *TP53* and *RB1* are commonly associated with the development of osteosarcoma \[[@R12]\].

There are many examples of "molecular targeted therapy", where tailored therapeutic agents have been selected to aim against specific molecules and their downstream effector pathways in each patient \[[@R13]\]. Nonetheless survival rates of patients have not greatly improved \[[@R14]\], as little is known at genetic level about the pathogenesis of osteosarcomas resulting in a lack of more effective and tailored chemotherapy drug regimens \[[@R15]\].

Our hypothesis is that only the analysis of the entire coding genome could lead to a better understanding of the molecular mechanisms underlying the development and progression of osteosarcoma. Next generation sequencing (NGS) technologies can unveil DNA sequences whose study can be applied to characterize both common and rare genomic alterations across cancer types. The NGS approach could clarify the landscape of genetic alteration in osteosarcoma and provide relevant biological data. In particular, the knowledge of genetic alterations in coding exon regions, through WES (Whole Exome Sequencing) approach, may result in an easier discovery of new proteins as molecular target which could be aimed at personalized therapies. Indeed, WES could lead to create algorithms to identify relevant genetic alterations networks relevant to the clinical context of the disease \[[@R16]--[@R18]\]. The aim of this study was to perform WES analysis in selected tumors samples of osteosarcoma, both from responder and non-responder patients that developed metastasis. The goal will be to improve the knowledge of osteosarcoma carcinogenesis, progression and resistance to therapy, to identify new strategies for therapeutic approaches and personalized therapy.

RESULTS {#s2}
=======

Sequence coverage and mutation analysis {#s2_1}
---------------------------------------

This analysis provided a vast new reservoir of data and, after filtering the data, within our discovery set of eight osteosarcomas, 5 responder and 3 non-responder, we identified 18,275 somatic variations in 8,247 genes. The number of coding variations in each sample ranged from 496 to 8,500 with an average of 2,347.5 variations. All the variations were missense and the 98.5% were SNVs (Single Nucleotide Variants) while the 1.5% were MNPs (Multiple Nucleotide Polymorphisms).

The mutation rate in the responder group was slightly higher than the non-responder group (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). Moreover, we found that, as in several other cancers \[[@R19]\], C:G\>T:A transitions were the most predominant somatic substitution both in the responder group (43%) and in the non-responder group (34%) and we found that the vast majority of these transitions were identified in the context of 5′-CpG-3′ dinucleotide as the result of a 5′-methylcytosine deamination (data not shown).

###### N° of variations and variation rate (n° of variations/Mb) of responder and non-responder osteosarcoma patients

  Sample   N° of variations   Variations rate   Status
  -------- ------------------ ----------------- ---------------
  1        1390               118.8             Responder
  5        8500               726.5             Responder
  6        496                42.4              Responder
  7        791                67.6              Responder
  8        802                68.5              Responder
  2        4211               359.9             Non-Responder
  3        1495               127.8             Non-Responder
  4        1095               93.6              Non-Responder

We did not find common mutated genes in all eight samples but we found three mutated genes (*KIF1B*, *NEB*, *KMT2C*) in 7/8 (87%) samples. Seventeen genes were mutated in 6 samples (75%, 6/8) and 57 genes showed variations in 5 samples (62.5%, 5/8). We noted a great variability of genes mutated among the samples as shown in [Supplementary Table 1](#SD2){ref-type="supplementary-material"}. Indeed, taking into consideration common mutated genes in at least 5 samples, we noted that sample n°5 showed variations in 77 genes while the sample n°6 showed variations only in 22 genes ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).

These 77 genes that were found mutated in more than half of the samples are involved in important biological processes such as transcription regulation, ion transport, DNA damage and repair, cell adhesion and angiogenesis (Table [2](#T2){ref-type="table"}).

![Histogram of the mutation rate in responder and non-responder group](oncotarget-08-80416-g001){#F1}

###### Genes mutated in more than half of the osteosarcoma patients and their biological functions

  Biological function                        Mutated genes
  ------------------------------------------ ---------------------------------------------------------------------------------------------
  Transcription regulation                   ATF2; BPTF; CHD7; DENND4A; HIVEP2; IKBKAP; JMJD1C; KMT2C; KMT2E; MYCBP2; NCOR1; RFX7; SPEN;
  Transport                                  ABCB5; ABCD2; ANKH; ATP10D; CACNA2D3; DGKD; HERC1; ITPR1; SLC8A1; SLC9B1; TRPM3;
  Cell Adhesion                              DST; FN1; ITGA6; MPDZ; NRXN2; RELN;
  Immunity                                   C5; CFH; PKHD1L1;
  Apoptosis                                  BIRC6; ITPR1; KIF1B;
  Endocytosis                                DGKD; LRP2; STAB2;
  Cell cycle                                 ALMS1; ATM; BIRC6; KMT2E;
  DNA damage                                 ATF2; ATM; DNA2; POLQ; PRDM10; PSME4;
  Angiogenesis                               FN1; THSD7A;
  Ubl conjugation pathway                    BIRC6; HECTD1; HERC1; MYCBP2;
  Wnt signaling pathway                      MACF1;
  Differentiation                            ABCB5; OBSCN; PSME4; THSD7A;
  DNA repair                                 DNA2; POLQ; PRDM10; PSME4;
  Muscle development                         DMD; NEB; SYNE1; UTRN;
  Regulation of bone mineralization          ENPP1; FBN2;
  Cell communication                         FRAS1;
  mRNA processing                            FRG1;
  Nucleotide metabolism                      NT5C2;
  Multicellular organism development         PRTG;
  Regulation of cell migration               SYNE2;
  Small GTPase mediated signal trasduction   DOCK5;
  Regulation of GTPase activity              AKAP13; DENND4A; PREX2; SYDE2;
  Extracellular matrix organization          EGFLAM;
  Microtuble-based movement                  DNAH9; DNAH10;

Despite variations of *TP53* and *RB1* are associated with development of human osteosarcoma, we found that variations of *TP53* were present in only one patient (12.5%, sample n°5) while only two patients showed variations of *RB1* gene (25%, sample n°1 and 5).

Genes that may be involved in osteosarcoma tumorigenesis {#s2_2}
--------------------------------------------------------

We found that *KIF1B*, *NEB* and *KMT2C* were the only three genes mutated in 7/8 samples. *KIF1B* is located on chromosome 1p36, and belongs to the kinesin superfamily of intermediate filaments \[[@R20]\]. *NEB*, maps to chromosome 2q22, encodes nebulin, a giant protein component of the cytoskeletal matrix \[[@R21]\]. We found 10 and 27 variations respectively in these two genes and they were mutated in all samples except in sample n°7, while sample n°5 had the higher number of variations in both cases (Table [3](#T3){ref-type="table"}). Finally, *KMT2C* is located on chromosome 7q36.1 and it is a member of the mixed-lineage leukemia (MLL) family and it has histone H3 lysine-specific methylation activity. KMT2C is an important component of histone H3 lysine 4 methyltransferase complex, implicated in chromatin remodelling, called ASCOM (ASC-2-and Mll3-containing complex) \[[@R22]\].

###### Somatic variation of KIF1B and NEB in osteosarcoma samples and their genomic and amino acid change

  Sample   Gene    Genomic change            Aminoacid      
  -------- ------- ------------------------- -------------- ---
  1        KIF1B   c.650C\>T                 p.Ser217Phe    
  1        KIF1B   c.5074G\>A                p.Asp1692Asn   
  1        NEB     c.21268C\>T               p.Pro7090Ser   
  1        NEB     c.21197T\>A               p.Leu7066His   
  2        KIF1B   c.177T\>A                 p.His59Gln     
  2        NEB     c.23803A\>G               p.Arg7935Gly   
  2        NEB     c.20167C\>G               p.Arg6723Gly   
  2        NEB     c.20167C\>T               p.Arg6723Trp   
  2        NEB     c.20165A\>G               p.Tyr6722Cys   
  2        NEB     c.20165A\>T               p.Tyr6722Phe   
  2        NEB     c.19249_19250delTAinsCA   p.Tyr6417His   
  2        NEB     c.19063T\>A               p.Tyr6355Asn   
  3        KIF1B   c.2798A\>G                p.Tyr933Cys    
  3        NEB     c.7325T\>A                p.Ile2442Asn   
  4        KIF1B   c.5069A\>G                p.Asp1690Gly   
  4        NEB     c.11109G\>C               p.Lys3703Asn   
  5        KIF1B   c.538G\>A                 p.Asp180Asn    
  5        KIF1B   c.2332G\>A                p.Val778Met    
  5        KIF1B   c.2344G\>A                p.Glu782Lys    
  5        NEB     c.23570A\>G               p.Glu7857Gly   
  5        NEB     c.22337T\>C               p.Ile7446Thr   
  5        NEB     c.22333G\>C               p.Asp7445His   
  5        NEB     c.22021G\>C               p.Ala7341Pro   
  5        NEB     c.21991G\>T               p.Ala7331Ser   
  5        NEB     c.21569C\>T               p.Thr7190Ile   
  5        NEB     c.18996G\>C               p.Gln6332His   
  5        NEB     c.18448G\>C               p.Asp6150His   
  5        NEB     c.11026G\>A               p.Asp3676Asn   
  5        NEB     c.8156A\>T                p.Asn2719Ile   
  5        NEB     c.8142T\>G                p.Asn2714Lys   
  5        NEB     c.2633G\>C                p.Ser878Thr    
  6        KIF1B   c.956C\>T                 p.Thr319Ile    
  6        NEB     c.9705C\>A                p.Asn3235Lys   
  6        NEB     c.7025G\>A                p.Ser2342Asn   
  8        KIF1B   c.3814C\>T                p.Arg1272Cys   
  8        NEB     c.10286C\>T               p.Thr3429Ile   
  8        NEB     c.9692T\>G                p.Leu3231Trp   L

Among these three genes, *KMT2C* showed the highest number of variations: we found 36 variations, with sample n°5 revealing the highest number of variations, except in sample n°3 (Table [4](#T4){ref-type="table"}). Particularly, sample n°3 was a 14-year old boy with diagnosis of high grade chondroblastic osteosarcoma made on femur biopsy (stage IVa), follow-up was 11 years, he did not respond to neoadjuvant chemotherapy and develop metastasis.

###### Somatic variations of KMT2C in osteosarcoma samples and their genomic and amino acid change

  Sample   Genomic change   Aminoacid
  -------- ---------------- --------------
  1        c.2963G\>T       p.Cys988Phe
  1        c.8326G\>A       p.Glu2776Lys
  1        c.11927C\>A      p.Pro3976Gln
  1        c.12014C\>T      p.Ser4005Phe
  1        c.14521G\>A      p.Gly4841Arg
  2        c.1277C\>A       p.Pro426Gln
  2        c.6632G\>C       p.Arg2211Thr
  2        c.5459C\>G       p.Ser1820Cys
  2        c.8174A\>G       p.Glu2725Gly
  2        c.9622T\>C       p.Ser3208Pro
  2        c.9617G\>C       p.Arg3206Thr
  4        c.10383T\>G      p.Asp3461Glu
  5        c.404C\>T        p.Ala135Val
  5        c.3155A\>T       p.Lys1052Ile
  5        c.3119C\>A       p.Pro1040Gln
  5        c.3029G\>T       p.Cys1010Phe
  5        c.5669G\>C       p.Arg1890Pro
  5        c.7318C\>T       p.Pro2440Ser
  5        c.7214A\>G       p.Glu2405Gly
  5        c.9182A\>G       p.Gln3061Arg
  5        c.9769G\>A       p.Glu3257Lys
  6        c.925C\>T        p.Pro309Ser
  6        c.1181G\>A       p.Cys394Tyr
  6        c.2512G\>A       p.Gly838Ser
  6        c.2468T\>C       p.Ile823Thr
  6        c.2459C\>T       p.Thr820Ile
  6        c.2656C\>T       p.Arg886Cys
  7        c.943G\>A        p.Gly315Ser
  7        c.925C\>T        p.Pro309Ser
  7        c.2512G\>A       p.Gly838Ser
  7        c.2468T\>C       p.Ile823Thr
  7        c.2963G\>T       p.Cys988Phe
  7        c.2917A\>G       p.Arg973Gly
  8        c.943G\>A        p.Gly315Ser
  8        c.2512G\>A       p.Gly838Ser
  8        c.2468T\>C       p.Ile823Thr

Genes that may be involved in osteosarcoma metastatic progression and resistance to therapy {#s2_3}
-------------------------------------------------------------------------------------------

We found that 0.18% (15/8247) of genes showed variations, all missense (94% SNV, 6% MNP), only in the non-responder group (Table [5](#T5){ref-type="table"}). Categorizing them by KEGG pathway analysis and literature review, we found that some of these are involved in important biological processes (Table [6](#T6){ref-type="table"}). *ERBB4* is located on chromosome 2q34 and it is a receptor tyrosine kinase member of the epidermal growth factor receptor (EGFR) family \[[@R23]\]. ERBB4 is involved in biological process such as signal transduction, transport and catabolism. It is involved in human disease like cancer: it participates in pathways such as ERBB signalling, implicated in tumor migration and invasion, and in other pathway implicated in inhibition of tumor angiogenesis \[[@R24]\]. In signal transduction, transport and catabolism and human disease biological process is involved THBS1 too and moreover is implicated in cell growth and death process. *THBS1*, thrombospondin 1, is located on chromosome 15q14 \[[@R25]\] and it is involved in RAP1 and TP53 signalling pathways, involved in inhibition of angiogenesis and metastasis, in PI3K-AKT and TGF-beta signalling pathway, involved in the control of cell cycle and apoptosis, and it takes part in focal adhesion and ECM-receptor interaction process \[[@R26]\]. Other genes are enzymes with specific activity like as rRNA and tRNA biogenesis (*DIS3*, *KARS*), spliceosome activity (*BCLAF1*) or charboidrate metabolism (*PDHX*) and all involved in carcinogenesis \[[@R27]--[@R32]\].

###### Variations of genes mutated only in non-responder group and their genomic and amino acid change

  Gene      Genomic change          Aminoacid
  --------- ----------------------- --------------
  ALDH1L2   c.484G\>A               p.Gly162Ser
  ALDH1L2   c.1732A\>C              p.Thr578Pro
  ALDH1L2   c.2086G\>A              p.Gly696Ser
  BCLAF1    c.491A\>C               p.Lys164Thr
  BCLAF1    c.1646T\>C              p.Leu549Pro
  BCLAF1    c.1742A\>T              p.Lys581Met
  CLCN1     c.823_825delGTCinsGGG   p.Val275Gly
  CLCN1     c.1289A\>C              p.Asn430Thr
  CLCN1     c.1574C\>G              p.Ala525Gly
  CLCN1     c.1073G\>A              p.Cys358Tyr
  CLCN1     c.1427C\>G              p.Thr476Ser
  COG3      c.943G\>C               p.Glu315Gln
  COG3      c.505A\>G               p.Thr169Ala
  COG3      c.1411T\>A              p.Tyr471Asn
  DIS3      c.2312_2313delTAinsAA   p.Ile771Lys
  DIS3      c.2252C\>G              p.Ala751Gly
  DIS3      c.2234C\>T              p.Thr745Ile
  DIS3      c.2458C\>T              p.Arg820Trp
  ERBB4     c.2761T\>A              p.Tyr921Asn
  ERBB4     c.1541G\>A              p.Gly514Glu
  ERBB4     c.1841G\>A              p.Cys614Tyr
  KARS      c.398T\>C               p.Leu133Pro
  KARS      c.1009G\>T              p.Val337Phe
  KARS      c.1066G\>A              p.Asp356Asn
  OR52N1    c.589A\>G               p.Asn197Asp
  OR52N1    c.569C\>G               p.Ser190Cys
  OR52N1    c.53G\>C                p.Gly18Ala
  OR52N1    c.82T\>C                p.Trp28Arg
  PDE6C     c.646T\>A               p.Tyr216Asn
  PDE6C     c.650T\>C               p.Leu217Pro
  PDE6C     c.1289G\>A              p.Gly430Glu
  PDE6C     c.1992G\>T              p.Leu664Phe
  PDHX      c.566G\>C               p.Arg189Pro
  PDHX      c.626G\>A               p.Gly209Glu
  PDHX      c.323G\>A               p.Gly108Glu
  SCN8A     c.2276T\>C              p.Ile759Thr
  SCN8A     c.4048G\>A              p.Ala1350Thr
  SCN8A     c.677G\>A               p.Arg226Lys
  SP140L    c.1425A\>C              p.Lys475Asn
  SP140L    c.329T\>A               p.Leu110His
  SP140L    c.1013C\>A              p.Pro338His
  THBS1     c.634C\>G               p.Leu212Val
  THBS1     c.1699_1700delGAinsGT   p.Asp567Val
  THBS1     c.2365G\>A              p.Asp789Asn
  THBS1     c.1532G\>C              p.Gly511Ala
  UBE4A     c.1130T\>A              p.Ile377Asn
  UBE4A     c.2209G\>A              p.Glu737Lys
  UBE4A     c.3136G\>T              p.Asp1046Tyr
  ZNF12     c.137C\>G               p.Ser46Cys
  ZNF12     c.1265C\>T              p.Ser422Phe
  ZNF12     c.2086C\>T              p.Leu696Phe

###### Mutated genes in non-responder group of osteosarcoma patients and their chromosomal location and biological process

  Gene      Chromosomal location   Biological process
  --------- ---------------------- ------------------------------------------------------------------------------------
  ALDH1L2   12q23.3                Metabolism of cofactors and vitamins
  BCLAF1    6q23.3                 Spliceosome
  CLCN1     7q34                   Ion channels
  COG3      13q14.13               Membrane trafficking
  DIS3      13q22.1                mRNA biogenesis
  ERBB4     2q34                   Signal trasduction, Transport and catabolism, Human disease
  KARS      16q23.1                tRNA biogenesis
  OR52N1    11p15.4                Olfactory transduction
  PDE6C     10q24                  Sensory transduction
  PDHX      11p13                  Carbohydrate metabolism
  SCN8A     12q13                  Ion channels
  SP140L    2q37.1                 unknown
  THBS1     15q15                  Signal trasduction, Transport and catabolism, Human disease, Cell growth and death
  UBE4A     11q23.3                Ubiquitin mediated proteolysis
  ZNF12     7p22.1                 Transcription factors

DISCUSSION {#s3}
==========

Osteosarcoma is a heterogeneous tumor and it is a so-called "orphan cancer" with no known driver oncogenes \[[@R33]\]. It is essential to find useful biomarkers and to detect the potential targets for new drugs, to increase overall survival of these patients. This could be done only if we better understand the complex biology of this tumor and the molecular pathways that lead to the development of metastases and resistance to therapy. At present time, the most innovative approach is represented by NGS, which allows to analyse the entire human genome \[[@R18]\]. In this study, we performed the analysis of exomic sequences of osteosarcomas to advance our understanding of their genetic underpinnings and to correlate the genetic alterations with the clinical and pathological features of each patient. Our aim was to identify clinically relevant variations in the landscape of somatic events in osteosarcoma pathogenesis and so we performed WES analysis on eight high grade osteosarcoma biopsies. Using stringent criteria for the analysis of these presumptive variations, we identified 18,275 somatic variations, all missense, in 8,247 genes. We noted that the mutation rate was similar between responder and non-responder group but overall this rate was higher than previous studies probably due to the small number of our samples \[[@R34]--[@R36]\]. We did not find specific structural abnormalities common to all samples, such as specific translocations like other sarcomas (e.g. Ewing sarcoma EWS/FLI1 t(11;22)(q24;q12)), confirming the complexity of osteosarcoma karyotype \[[@R15]\]. Despite *TP53* and *RB1* genes are considered top driver genes in osteosarcoma cancerogenesis, our study showed lower mutation frequency of *TP53* and *RB1* than other studies \[[@R34],[@R35],[@R37]--[@R39]\]. Indeed, we observed that only one patients (12.5%, 1/8) showed variations of *TP53* gene and that only two patients showed variations of *RB1* gene (25%, 2/8). Our results could be the effect of the small number of samples, however the range of mutation rate described in osteosarcoma is very large going from 31% to 82% and from 19% to 64% for *TP53* and *RB1* respectively \[[@R41]\]. Moreover, most *TP53* mutations described in some studies, are structural variations in intron 1 \[[@R34], [@R37], [@R38]\] that we did not study and the mutation rate outside the intron 1 is low (19--20%) \[[@R34], [@R40]\]. However, as reported in literature, among all mutations of *TP53* reported in previous studies only some mutations are clonal events \[[@R37]\]. Lastly, our data was filtered by Sift and Polyphen-2 bioinformatics software, so we reported only mutations that are considered deleterious for the protein function.

However, beyond *TP53* and *RB1*, between genes considered candidate driver genes in osteosarcoma carcinogenesis \[[@R36]\] we found that *ATM*, a gene involved in DNA damage control signalling pathway, showed variations in 5/8 osteosarcoma samples. *ATM* is a tumor suppressor gene that belongs to the family of proteins that respond to DNA damage by phosphorylating key substrates involved in DNA repair and/or cell cycle control \[[@R36]\]. Moreover, we did not find variations in genes associated at inherited cancer predisposition syndromes associated with osteosarcoma as *RECQL4*, *BLM*, and *WRN* \[[@R34], [@R35], [@R37]\].

Moreover, we did not find variations common to all osteosarcoma samples but we found three mutated genes in 7/8 samples (87%) never studied in osteosarcoma. Variations in these three genes may be early molecular events and so they may be related to osteosarcoma tumorigenesis. KIF1B is responsible for intracellular vesicular transport \[[@R20]\], a process involved in the production matrix in osteosarcoma \[[@R42]\]. KIF1B has been shown to act as a tumor suppressor in multiple cancers by acting on various inhibitors of cell proliferation and activators of apoptosis \[[@R20]\]. Another interesting *NEB*, maps to chromosome 2q22, encodes nebulin, a giant protein component of the cytoskeletal matrix \[[@R21]\], that coexists with thick and thin filaments within the sarcomeres of skeletal muscle \[[@R21]\].

Finally, KMT2C catalyses the monomethylation of H3K4 in collaboration with hormone receptors and transcription factors involved in developmental signalling \[[@R22], [@R43]\]; it is one of the histone modifiers previously implicated in some cancer types \[[@R22]\]. It caught our attention showing more variations than *KIF1B* and *NEB*, finally because this gene is found to be inactivated in other tumors causing an alteration of tumor suppressor gene *TP53* \[[@R43]\], which is also frequently altered in osteosarcoma \[[@R44]\]. Moreover, recent evidence showed that mutations of *KMT2C* can modify its cooperation with oestrogen receptor \[[@R45]\], this hormone playing a key role in the development and support of bone remodelling and matrix production \[[@R46]\]. Recently, it has been demonstrated that highly conserved epigenetic regulators are frequently mutated in cancer \[[@R47]\]; indeed, some studies suggest that variations in the coding sequences of regulatory elements, that act on enhancers to recognize specific transcription factors, could be the cause of tumor development \[[@R47]\]. KMT2C acts in collaboration with hormone receptors and transcription factors involved in growth-promoting pathways and it performs its action at transcription enhancer regions \[[@R22]\]. *KMT2C* is frequently mutated in a broad spectrum of cancers and it has been related to tumorigenesis \[[@R48]\]. Therefore, our hypothesis is that KMT2C could be involved in osteosarcoma carcinogenesis too.

We found that the responder group showed more variations than the non-responder group and we noted that 15 genes showed variations only in the non-responder group which subsequently developed a metastatic disease. We found that some of them are involved in carcinogenesis and tumor progression but not in osteosarcoma. Particularly, ERBB4 is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily that regulates cell proliferation and differentiation \[[@R23]\]. It has been shown that ERBB4 is overexpressed in Ewing Sarcoma cell lines derived from chemoresistant or metastatic Ewing sarcoma, a tumor of the bone \[[@R24]\]. ERBB4 leads to activation of PI3K-AKT, focal adhesion kinase (FAK) and the RAC1 GTPase, a mediator of cell migration and invasion \[[@R24]\], pathways that are already been described in osteosarcoma pathogenesis \[[@R49]--[@R50]\].

*ERBB4* is rarely mutated in human cancers \[[@R51]\] but recently it was shown that ERBB4 can inhibit the tumor suppressor TP53 by regulating the MDMX-MDM2 complex stability, the primary inhibitors of TP53, leading to TP53 inactivation in tumor \[[@R52]\]. Thrombospondin I (THBS1) is an endogenous inhibitor of angiogenesis, which limits blood vessel density in normal tissues and curtails tumor growth. It interacts with a variety of ECM molecules and cell surface receptors and this protein has been shown to play roles in tumorigenesis; particularly, it was showed that THBS1 induced cell migration in several tumor cell lines suggesting that THBS1 is involved in cancer invasion \[[@R26]\]. DIS3 is one of catalytic components of the human RNA processing and degrading exosome it has both endonucleolytic and 3-prime/5-prime exonucleolytic activity \[[@R27]\]; mutations in *DIS3* have been observed in several cancer types \[[@R28]\] and in multiple myeloma was observed a shorter survival in patients with *DIS3* mutations \[[@R29]\]. *BCLAF1* encodes a transcriptional repressor that interacts with several members of the BCL2 family of proteins and ectopical *BCLAF1* expression induces apoptosis in various cell types or autophagic cell death in myeloma cells. It was hypothesized that BCLAF1 plays a critical role repressing the transcription of survival genes through TP53 inhibition. Moreover, it was found that tumor cells suppress *BCLAF1* expression inducing a cascade of antiapoptotic cellular events that all together determine an increase survival of tumor cells \[[@R31]\]. The *KARS* gene encodes lysyl-tRNA synthetase, which catalyses the aminoacylation of tRNA-lys in the cytoplasm and mitochondria. It was showed that it was implicated in cancer metastasis indeed the phosphorylation of KARS at the Thr52 residue by p38MAPK, causes the dissociation from the cytosolic multi-tRNA synthetase complex and the following translocation to the plasma membrane, where it associates with a 67 kDa laminin receptor (p67LR) involved in migration and metastasis \[[@R30]\]. The *PDHX* gene encodes component X of the pyruvate dehydrogenase (PDH) complex that is in the mitochondrial matrix and catalyzes the conversion of pyruvate to acetyl coenzyme A \[[@R32]\]. It was showed that in colorectal cancer cells the glucose metabolism was regulated by miR-26a direct targeting the PDHX, which inhibits the conversion of pyruvate to acetyl coenzyme A in the citric acid cycle to require the glucose uptake to the energy needs of cancer cells \[[@R32]\]. In successive studies, it will be necessary to study whether and how these mutations may modify the expression of these genes and the function of the associated protein to discovery a possible molecular target.

Some of these genes identified in our study are involved in metastatic progression and poor survival in tumors, also of mesenchymal origin, but these have never been studied in osteosarcoma \[[@R24], [@R26], [@R29], [@R30]\]. Our hypothesis is that alterations in these genes could be involved in a mechanism of metastatic progression and drug resistance in osteosarcoma.

We recognize these preliminary results may arise due to the small sample size, which is a limitation of the study, and we believe that it will be necessary first to ascertain our data in a larger cohort of patients.

In conclusion, our WES analysis confirms that the osteosarcoma karyotype is complex, however, we found genes probably involved in osteosarcoma carcinogenesis, as *KMT2C*, and we identified a group of 15 genes probably involved in metastasis development and drug resistance that could offer the opportunity to identify potential drug targets in order to create a personalized therapy and increase the survival rate among young patients with osteosarcoma.

MATERIALS AND METHODS {#s4}
=====================

Population study {#s4_1}
----------------

The population of this study included 8 diagnostic biopsies of patients with conventional high grade osteosarcoma (sec. Enneking classification) obtained before neoadjuvant therapy from the files of the Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, ICOT, Latina, Italy. The WHO 2008 classification of bone tumors was used for classifying and staging the bone lesions. Patients had a mean follow-up time of 9 years (range 1--14 years), 50% of them showed a minimum 5-years overall survival. Evaluation of response to therapy was assessed by percentage area of necrosis in the specimen after surgery; out of these 8 patients, 5 (identified as "responder") responded to therapy showing tumor necrosis ≥ 90% after surgery and didn\'t develop metastasis while 3 patients did not respond to neoadjuvant chemotherapy showing tumor necrosis ≤ 90% after surgery and developed metastasis (identified as "non-responder"). There were not inherited cancer predisposition syndromes associated with osteosarcoma among our samples. The clinical and pathological characteristics of each osteosarcoma patients are described in Table [7](#T7){ref-type="table"}. All the tissue samples were reviewed on microscopy examinations by two dedicated pathologists.

###### Clinicopathological characteristics of 8 osteosacoma patients

  Sample   Sex   Age   Histological type\*           Grading\*\*   Staging\*   Site       Follow-up (Years)   Status
  -------- ----- ----- ----------------------------- ------------- ----------- ---------- ------------------- ---------------
  1        F     29    Conventional Osteosarcoma     High grade    IIB         Jaw        14                  Responder
  2        M     30    Conventional Osteosarcoma     High grade    III         Femur      3                   Non-Responder
  3        M     14    Chondroblastic osteosarcoma   High grade    IVA         Femur      11                  Non-Responder
  4        M     35    Conventional Osteosarcoma     High grade    III         Femur      1                   Non-Responder
  5        M     21    Conventional Osteosarcoma     High grade    III         Femur      13                  Responder
  6        M     11    Conventional Osteosarcoma     High grade    III         Femur      5                   Responder
  7        F     24    Conventional Osteosarcoma     High grade    IIB         Mandible   12                  Responder
  8        M     31    Chondroblastic osteosarcoma   High grade    IIA         Jaw        13                  Responder

\*Sec. WHO 2008

\*\* Sec. Enneking grade

Whole-exome sequencing (WES) {#s4_2}
----------------------------

Genomic DNA was extracted from FFPE osteosarcoma biopsies using RecoverAll Total Nucleic Acid isolation FFPE kit (Life Technologies, Foster City, CA) according to the manufacturer\'s instruction and was used to prepare fragment libraries suitable for massively parallel paired-end sequencing.

DNA was amplified with GenomePlex Single Cell Whole Genome Amplification kit, following the manufacturer\'s protocol, because of the degraded material, typical of osteosarcoma samples. We measured DNA concentration of the samples using Qubit 2.0 Fluorometer (Invitrogen, Life Technologies, Grand Island, NY) with the Qubit DNA HS assay kit or Qubit DNA BR Assay kit according to the quantity of the starting material. Moreover, we checked the quality of DNA with 2200 Tapestation Instrument (Agilent Technologies, Santa Clara, CA, USA) using the D1000 screen tape or the High sensitivity D1000 screen tape as appropriate, to see the level of fragmentation of our samples.

To prepare the DNA library we used Nextera Rapid Capture Expanded Exome Kit (Illumina, San Diego, CA, USA) following the guidelines of the protocol but we used the half of the amount of the fragmentation enzyme because of the high level of fragmentation of all the samples tested with Tapestation. We load a maximum of 5 pooling libraries for each cartridge NextSeq High Output (300 cycles) on NextSeq500 (Illumina, San Diego, CA, USA).

WES data analysis {#s4_3}
-----------------

We sequenced the whole exomes of eight high-grade osteosarcoma tissues using NextSeq550 Illumina platform. The instrument generated approximately an average read length of 120.6 bases. After mapping to the human reference genome GRCh37 (hg19) using Burrows-Wheeler Alignment tool (BWA), we obtained the average depth of each base in the target regions as 17.7x. The average coverage of target regions was 121.7x.

The raw data generated from Illumina NextSeq550 were converted using Bcl2toFastq tools provided by Illumina. The data analysis of exomes was performed by using the SeqMule pipeline1. The final Variant Call Format files (VCFs) were uploaded on the VariantStudio Illumina (Illumina San Diego, CA, USA) software to perform annotation and filtration steps. We filtered genomic data by quality score of 30, by mean read depth of 5, and by GMAF ≤ 1 (Global Minor Allele Frequency: the frequency of the second most frequent allele in the population). Next, the detected mutations were filtered for the variants absent in database of Single Nucleotide Polymorphisms (dbSNP) to distinguish known somatic mutations from germline mutations. We further selected the somatic variations in the coding sequence by excluding those variations in flanking sequences like splicing sites, 5ʹ-UTR, 3ʹUTR, introns and intergenic regions. Moreover, we performed bioinformatics analysis using SIFT (v4.0.3) and PolyPhen-2 (v2.1.0) tools, that predict whether an amino acid substitution affects protein function based on sequence homology. To be sure that the variations to study were only those that caused a protein alteration, we selected only those that were at the same time deleterious for SIFT and probably damaging for PolyPhen-2.

Validation of variations {#s4_4}
------------------------

Genes that showed variation in the 87% of osteosarcoma samples (*KIF1B*, *NEB* and *KMT2C*) were selected for target resequencing and validation by Sanger sequencing. DNAs were amplified using the Gene Amp PCR System 9700 (Life Technologies, Foster City, CA). The PCR products were then purified using Exosap-IT (Affymetrix, Santa Clara, CA) and then sequenced using Big Dye Terminator version 1.1 Cycle Sequencing Kit (Life Technologies, Foster City, CA). Unincorporated primers and dye terminators were removed using the Montage-SEQ96 Sequencing Reaction Cleanup Kit (Merck Millipore, Billerica, MA). Sequencing was performed on an ABI PRISM 3100 Genetic Analyzer (Life Technologies, Foster City, CA) with 3100 Genetic Analyzer Data Collection software version 1.1. The sequencing and each reaction were performed in triplicate.
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NGS

:   Next Generation Sequencing

WES

:   Whole Exome Sequencing

BWA

:   Burrows-Wheeler Alignment

SNV

:   Single Nucleotide Variant

MNP

:   Multiple Nucleotide Polymorphisms

KIF1B

:   Kinesin Family member 1B

NEB

:   Nebulin

KMT2C

:   lysine (K)-specific Methyltransferase 2C

TP53

:   Tumor Protein 53

RB1

:   Retinoblastoma 1

MLL

:   Mixed-Lineage Leukemia

ASCOM

:   ASC-2-and Mll3-containing complex

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

ERBB4

:   Erb-b2 receptor tyrosine kinase 4

EGFR

:   Epidermal Growth Factor Receptor

THBS1

:   Thrombospondin 1

RAP1

:   (Ras-proximate-1)

PI3K

:   Phosphoinositide 3-Kinase

AKT

:   Serine/Threonine Kinase 1

TGF-BETA

:   transforming growth factor, beta 1

ECM

:   Extra-Cellular Matrix

DIS3

:   DIS3 homolog, exosome endoribonuclease and 3′-5′ exoribonuclease

KARS

:   lysyl-tRNA synthetase

BCLAF1

:   BCL2 associated transcription factor 1

PDHX

:   pyruvate dehydrogenase complex component X

EWS

:   EWS RNA binding protein 1

FLI1

:   Fli-1 proto-oncogene, ETS transcription factor

FAK

:   Focal Adhesion Kinase

RAC1

:   ras-related C3 botulinum toxin substrate 1

GTP

:   Guanosine Triphosphate

MDMX

:   MDM4, p53 regulator

MDM2

:   MDM2 proto-oncogene

p38MAPK

:   p38 Mitogen-Activated Protein Kinases

p67LR

:   Laminin Receptor

PHD

:   Pyruvate Dehydrogenase

FFPE

:   Formalin-Fixed Paraffin Embedded

VCF

:   Variant Call Format

GMAF

:   Global Minor Allele Frequency

UTR

:   Untraslated Region
